The AURKA–PTTG1 signaling axis induces enzalutamide resistance in prostate cancer

Evaluation of Alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial

10.1001/jamaoncol.2022.7949 · doi-reference

CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine

10.3389/fendo.2022.1106175 · doi-reference

Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis

10.1016/j.redox.2024.103137 · doi-reference

The cellular geography of aurora kinases

10.1038/nrm1245 · doi-reference

EIF4A3-Induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling

10.1158/0008-5472.can-21-2988 · doi-reference

PTTG1-mediated reprogramming of asparagine metabolism enhances DNA damage repair and leads to compromised antitumor immunity in prostate cancer

10.1016/j.urolonc.2025.09.005 · doi-reference

The PTTG1/VASP axis promotes oral squamous cell carcinoma metastasis by modulating focal adhesion and actin filaments

10.1002/1878-0261.13779 · doi-reference

Inhibition of PTTG1 suppresses proliferation and promotes differentiation of neuroblastoma cells by inducing autophagy

10.1007/s00383-025-06246-w · doi-reference

Phosphorylated PTTG1 switches its subcellular distribution and promotes beta-catenin stabilization and subsequent transcription activity

10.1038/s41388-023-02767-7 · doi-reference

Integrating quantitative proteomics with accurate genome profiling of transcription factors by greenCUT&RUN

10.1093/nar/gkab038 · doi-reference

Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA

10.1080/07853890.2023.2282184 · doi-reference

Neurokinin-1 receptor drives PKCa-AURKA/N-myc signaling to facilitate the neuroendocrine progression of prostate cancer

10.1038/s41419-023-05894-x · doi-reference

HMMR promotes prostate cancer proliferation and metastasis via AURKA/mTORC2/E2F1 positive feedback loop

10.1038/s41420-023-01341-0 · doi-reference

The oncogenic role of AURKA in gastric cancer: mechanisms, pathways, and clinical relevance

10.1093/carcin/bgaf054 · doi-reference

Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features

10.1186/s13058-024-01882-x · doi-reference

Aurora kinases, emerging critical targets for cancer treatment and related new therapeutic strategies

10.1016/j.bioorg.2025.108633 · doi-reference

Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression

10.1111/cas.13493 · doi-reference

CDC20 and PTTG1 are important biomarkers and potential therapeutic targets for metastatic prostate cancer

10.1007/s12325-021-01729-3 · doi-reference

A comprehensive pan-cancer analysis for pituitary tumor-transforming gene 1

10.3389/fgene.2022.843579 · doi-reference

Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity

10.1016/j.heliyon.2023.e13201 · doi-reference

Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance

10.1186/s12885-024-13060-5 · doi-reference

Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression

10.1083/jcb.200506119 · doi-reference

Basic mechanism of eukaryotic chromosome segregation

10.1098/rstb.2004.1615 · doi-reference

PD44-12 enzalutamide enhances glycolysis in castration-resistant prostate cancer

10.1097/ju.0000000000002058.12 · doi-reference

Glycolysis-induced drug resistance in tumors-A response to danger signals?

10.1016/j.neo.2020.12.009 · doi-reference

Modulating glycolysis to improve cancer therapy

10.3390/ijms24032606 · doi-reference

The neglected liaison: targeting cancer cell metabolic reprogramming modifies the composition of non-malignant populations of the tumor microenvironment

10.3390/cancers13215447 · doi-reference

Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced?

10.3390/cancers13020327 · doi-reference

Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management

10.1097/mou.0000000000000984 · doi-reference

Prostate cancer

10.1016/s0140-6736(21)00950-8 · doi-reference